	US 12,344,658 B2
	Nanoparticle formulations
Brian Curtis Turner, Denver, CO (US); Yosef Refaeli, Denver, CO (US); and Gregory Alan Bird, Littleton, CO (US)
Assigned to HTYR Acquistion LLC, Philadelphia, PA (US)
Filed by HTYR Acquistion LLC, Philadelphia, PA (US)
Filed on Jul. 27, 2021, as Appl. No. 17/386,437.
Application 17/386,437 is a division of application No. 16/742,082, filed on Jan. 14, 2020, granted, now 11,116,796, issued on Sep. 14, 2021.
Application 16/742,082 is a division of application No. 15/828,971, filed on Dec. 1, 2017, granted, now 10,583,156, issued on Mar. 10, 2020.
Claims priority of provisional application 62/429,466, filed on Dec. 2, 2016.
Prior Publication US 2022/0096545 A1, Mar. 31, 2022
Int. Cl. C07K 14/82 (2006.01); A61K 38/00 (2006.01); A61P 37/02 (2006.01); B82Y 5/00 (2011.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 14/73 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 14/82 (2013.01) [B82Y 5/00 (2013.01); C07K 14/4702 (2013.01); C07K 14/7051 (2013.01); C07K 14/70514 (2013.01); C07K 14/70517 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61P 37/02 (2018.01); C07K 2319/10 (2013.01); C07K 2319/41 (2013.01); C12N 2501/606 (2013.01)]

19 Claims

1. A method of increasing one or more of activation, survival, or proliferation of one or more immune cells or increasing an immune response in a subject in need thereof by administering to the subject a therapeutically effective amount of a formulation comprising a population of biologically active nanoparticles comprising one or more MYC-containing polypeptides wherein:

a) the average diameter of the biologically active nanoparticles is between about 80 nm and about 150 nm;

b) the pH of the formulation is at least about pH 6.0, and no greater than about pH 8; and

c) the one or more MYC-containing polypeptides comprises a MYC fusion protein, comprising a protein transduction domain linked to a MYC polypeptide.